Activation of final complement components after kidney transplantation as a marker of delayed graft function severity.

biomarkers, complement delayed graft function kidney biopsy kidney transplantation

Journal

Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 07 03 2020
entrez: 12 4 2021
pubmed: 13 4 2021
medline: 13 4 2021
Statut: epublish

Résumé

Ischaemia-reperfusion (I/R) damage is a relevant cause of delayed graft function (DGF). Complement activation is involved in experimental I/R injury, but few data are available from kidney transplant (KT) patients. We studied the dynamics of membrane attack complex (C5b-9) as a soluble fraction (SC5b-9) and the histological deposit pattern of C3b, complement Factor H (FH) and C5b-9 in DGF patients. We evaluated SC5b-9 levels in 59 recipients: 38 with immediate graft function and 21 with DGF. The SC5b-9 was measured at admission for KT and 7 days after KT. DGF-kidney biopsies ( SC5b-9 increased significantly in DGF patients (Day 0: 6621 ± 2202 mAU/L versus Day 7: 9626 ± 4142  mAU/L; P = 0.006), while it remained stable in non-DGF patients. Days 0-7 increase >5% was the better cut-off associated with DGF versus non-DGF patient discrimination (sensitivity = 81%). In addition, SC5b-9 increase was related to DGF duration and worse graft function, and independently associated with DGF occurrence. SC5b-9, C3b and FH stains were observed in tubular epithelial cells basal membrane. DGF-kidney biopsies showed a more frequently high-intensity stain, a higher number of tubules with positive stain and larger perimeter of tubules with positive stains for SC5b-9, C3b and FH than control patients. Both SC5b-9 levels and SC5b-9, C3b and FH deposits in tubular epithelial cells basal membrane are highly expressed in patients experiencing DGF. SC5b-9 levels increase could be useful as a marker of DGF severity.

Sections du résumé

BACKGROUND BACKGROUND
Ischaemia-reperfusion (I/R) damage is a relevant cause of delayed graft function (DGF). Complement activation is involved in experimental I/R injury, but few data are available from kidney transplant (KT) patients. We studied the dynamics of membrane attack complex (C5b-9) as a soluble fraction (SC5b-9) and the histological deposit pattern of C3b, complement Factor H (FH) and C5b-9 in DGF patients.
METHODS METHODS
We evaluated SC5b-9 levels in 59 recipients: 38 with immediate graft function and 21 with DGF. The SC5b-9 was measured at admission for KT and 7 days after KT. DGF-kidney biopsies (
RESULTS RESULTS
SC5b-9 increased significantly in DGF patients (Day 0: 6621 ± 2202 mAU/L versus Day 7: 9626 ± 4142  mAU/L; P = 0.006), while it remained stable in non-DGF patients. Days 0-7 increase >5% was the better cut-off associated with DGF versus non-DGF patient discrimination (sensitivity = 81%). In addition, SC5b-9 increase was related to DGF duration and worse graft function, and independently associated with DGF occurrence. SC5b-9, C3b and FH stains were observed in tubular epithelial cells basal membrane. DGF-kidney biopsies showed a more frequently high-intensity stain, a higher number of tubules with positive stain and larger perimeter of tubules with positive stains for SC5b-9, C3b and FH than control patients.
CONCLUSIONS CONCLUSIONS
Both SC5b-9 levels and SC5b-9, C3b and FH deposits in tubular epithelial cells basal membrane are highly expressed in patients experiencing DGF. SC5b-9 levels increase could be useful as a marker of DGF severity.

Identifiants

pubmed: 33841865
doi: 10.1093/ckj/sfaa147
pii: sfaa147
pmc: PMC8023215
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1190-1196

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA.

Références

Nat Rev Immunol. 2009 Oct;9(10):729-40
pubmed: 19730437
Transplantation. 1997 Apr 15;63(7):968-74
pubmed: 9112349
Ann Surg. 2009 Jun;249(6):889-99
pubmed: 19474697
Transplantation. 2008 Apr 15;85(7):923-7
pubmed: 18408568
Transplantation. 2013 Mar 27;95(6):816-20
pubmed: 23348894
Clin J Am Soc Nephrol. 2012 Nov;7(11):1843-51
pubmed: 22904122
Transplant Rev (Orlando). 2012 Oct;26(4):280-90
pubmed: 22902496
Annu Rev Immunol. 2005;23:821-52
pubmed: 15771587
Kidney Int. 2005 Feb;67(2):524-30
pubmed: 15673300
Kidney Blood Press Res. 2018;43(5):1655-1665
pubmed: 30380547
Immunobiology. 2012 Feb;217(2):225-34
pubmed: 21856033
J Immunol. 2006 Oct 1;177(7):4727-34
pubmed: 16982912
Cell Tissue Res. 2011 Jan;343(1):227-35
pubmed: 20838815
Eur J Immunol. 2018 May;48(5):791-802
pubmed: 29389016
Kidney Int. 1989 Aug;36(2):257-65
pubmed: 2528653
Curr Transplant Rep. 2019 Mar;6(1):52-59
pubmed: 31673484
Nephrol Dial Transplant. 2009 Mar;24(3):1039-47
pubmed: 19103734
EBioMedicine. 2018 Feb;28:31-42
pubmed: 29398595
Mol Immunol. 2010 Aug;47(13):2187-97
pubmed: 20580090
Biomed Res Int. 2014;2014:361065
pubmed: 24967359
Mol Immunol. 1980 Jan;17(1):9-20
pubmed: 7360115
Am J Physiol Renal Physiol. 2011 Apr;300(4):F932-40
pubmed: 21289051
J Clin Invest. 2000 May;105(10):1363-71
pubmed: 10811844
Am J Transplant. 2010 Oct;10(10):2279-86
pubmed: 20883559
Clin Sci (Lond). 1990 Nov;79(5):471-6
pubmed: 2174314
Kidney Int. 2011 Jul;80(2):165-73
pubmed: 21544060

Auteurs

Carlos E Arias-Cabrales (CE)

Department of Nephrology, Hospital del Mar, Barcelona, Catalunya, Spain.

Marta Riera (M)

Department of Nephrology, Hospital del Mar, Barcelona, Catalunya, Spain.
Institut Hospital del Mar d'Investigacions Mèdiques, IMIM, Barcelona, Catalunya, Spain.

María José Pérez-Sáez (MJ)

Department of Nephrology, Hospital del Mar, Barcelona, Catalunya, Spain.

Javier Gimeno (J)

Department of Pathology, Hospital del Mar, Barcelona, Catalunya, Spain.

David Benito (D)

Department of Nephrology, Hospital del Mar, Barcelona, Catalunya, Spain.
Institut Hospital del Mar d'Investigacions Mèdiques, IMIM, Barcelona, Catalunya, Spain.

Dolores Redondo (D)

Department of Nephrology, Hospital del Mar, Barcelona, Catalunya, Spain.

Carla Burballa (C)

Department of Nephrology, Hospital del Mar, Barcelona, Catalunya, Spain.

Marta Crespo (M)

Department of Nephrology, Hospital del Mar, Barcelona, Catalunya, Spain.

Julio Pascual (J)

Department of Nephrology, Hospital del Mar, Barcelona, Catalunya, Spain.

Eva Rodríguez (E)

Department of Nephrology, Hospital del Mar, Barcelona, Catalunya, Spain.

Classifications MeSH